Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck increased its revenue outlook for the year due to growth in sales of new drugs. The company simultaneously reduced its profit guidance, citing charges related to its acquisition of Terns Pharmaceuticals.

Next story